Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Alessia De Stefano, BSc, Valentina Indio, PhD, Annalisa Astolfi, PhD, Andrea Pellagatti, Stefano Ratti, MD, Miriam Fogli, PhD, Sarah Parisi, MDPhD, Andrea Pession, Michele Cavo, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, Carlo Finelli

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136942

Published: 2020

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2018) 132 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2018-99-117714

Published: 2018

Journal Articles

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Y Follo, PhD, Andrea Pellagatti, PhD, Richard N Armstrong, PhD, Stefano Ratti, MD, Sara Mongiorgi, PhD, Annalisa Astolfi, PhD, Valentina Indio, PhD, Cristina Clissa, MD PhD, Domenico Russo, MD, Marco Gobbi, MD, Marilena Barraco, PhD, Sarah Parisi, MD PhD, Andrea Pession, MD, Michele Cavo, MD, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, PhD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 5299.

https://doi.org/10.1182/blood.V130.Suppl_1.5299.5299

Published: 2017

Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2016) 128 (22): 3169.

https://doi.org/10.1182/blood.V128.22.3169.3169

Published: 2016

Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD

Blood (2016) 128 (22): 5091.

https://doi.org/10.1182/blood.V128.22.5091.5091

Published: 2016

Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Blood (2015) 126 (23): 2871.

https://doi.org/10.1182/blood.V126.23.2871.2871

Published: 2015

Journal Articles

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Y Follo, PhD, Marta Stanzani, MD PhD, Paolo Avanzini, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, MD, Gian Matteo Rigolin, MD, Patrizia Tosi, MD, Giuseppe Visani, MD, Lucio Cocco, MD, Michele Cavo, MD, Domenico Russo, MD PhD

Blood (2014) 124 (21): 4648.

https://doi.org/10.1182/blood.V124.21.4648.4648

Published: 2014

Journal Articles

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Matilde Y Follo, PhD, Carlo Finelli, Cristina Clissa, M.D., Sara Mongiorgi, PhD, Carmen Baldazzi, Marta Stanzani, MD, PhD, Michele Baccarani, MD, Lucio Cocco, MD

Blood (2013) 122 (21): 5227.

https://doi.org/10.1182/blood.V122.21.5227.5227

Published: 2013

Journal Articles

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Matilde Y Follo, PhD, Carlo Finelli, MD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Carla Filì, MD, Costanza Bosi, MD, Marilisa Quaranta, PhD, Stefania Paolini, MD, Anna Maria Billi, PhD, Marco Gobbi, MD, Michele Baccarani, MD, Domenico Russo, Giovanni Martinelli, MD, Lucia Manzoli, MD, Lucio Cocco, MD

Blood (2012) 120 (21): 1289.

https://doi.org/10.1182/blood.V120.21.1289.1289

Published: 2012

Journal Articles

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Carlo Finelli, M.D., Cristina Clissa, M.D., Maria Teresa Voso, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gianluca Gaidano, MD, PhD, Monica Crugnola, M.D., Maria Benedetta Giannini, M.D., Costanza Bosi, MD, Virginia Naso, MD, Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Giovanni Martinelli, Lucio Cocco, MD, Michele Baccarani, MD

Blood (2012) 120 (21): 4951.

https://doi.org/10.1182/blood.V120.21.4951.4951

Published: 2012

Journal Articles

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Matilde Y Follo, PhD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Francesca Chiarini, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, PhD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2011) 118 (21): 4635.

https://doi.org/10.1182/blood.V118.21.4635.4635

Published: 2011

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Blood (2010) 116 (21): 4029.

https://doi.org/10.1182/blood.V116.21.4029.4029

Published: 2010

Journal Articles

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Francesca Chiarini, BS, Stefania Paolini, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Lucia Manzoli, MD, Alberto M. Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD, PhD

Blood (2009) 114 (22): 2384.

https://doi.org/10.1182/blood.V114.22.2384.2384

Published: 2009

Journal Articles

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

Blood (2009) 114 (22): 4851.

https://doi.org/10.1182/blood.V114.22.4851.4851

Published: 2009

Journal Articles

The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.

James A. McCubrey, PhD, William L. Blalock, PhD, Pier Luigi Tazzari, MD, Alessandra Cappellini, PhD, Ilaria Iacobucci, PhD, Francesca Chiarini, BS, Steve L. Abrams, BS, Emanuela Ottaviani, PhD, Giovanni Martinelli, MD, Agostino Tafuri, MD, Lucio Cocco, MD PhD, Alberto M. Martelli, MD PhD, Federica Fala, MD

Blood (2007) 110 (11): 3344.

https://doi.org/10.1182/blood.V110.11.3344.3344

Published: 2007

Journal Articles

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

Carlo Finelli, MD, Matilde Y. Follo, PhD, Costanza Bosi, MD, Sara Mongiorgi, BS, Cristina Clissa, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Alberto M. Martelli, MD, PhD, Lucio Cocco, MD, PhD

Blood (2007) 110 (11): 2448.

https://doi.org/10.1182/blood.V110.11.2448.2448

Published: 2007

Journal Articles

Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients.

Costanza Bosi, MD, Carlo Finelli, MD, Alberto M. Martelli, MD, Maria Nyakern, Ph.D., Giovanni Martinelli, MD, Pier Luigi Tazzari, MD, Lucio Cocco, MD, Tiziana Grafone, PhD, Pier Paolo Piccaluga, MD, Baccarani Michele, MD

Blood (2005) 106 (11): 3432.

https://doi.org/10.1182/blood.V106.11.3432.3432

Published: 2005

NARROW

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.

The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only